These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38661518)

  • 1. Alginate/Carboxymethyl Chitosan Core-Shell Microspheres Coloaded with Doxorubicin/Docetaxel Reverse Chemotherapy Resistance in Anaplastic Thyroid Carcinoma.
    Zhou Y; Yang F; Zhou H; Lv S
    Thyroid; 2024 Jul; 34(7):856-870. PubMed ID: 38661518
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
    Wang W; Zhou J; Zhao L; Chen S
    Biomed Pharmacother; 2017 Apr; 88():985-990. PubMed ID: 28178630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer Cells
    Xiong L; Lin XM; Nie JH; Ye HS; Liu J
    Nanotheranostics; 2021; 5(2):143-154. PubMed ID: 33457193
    [No Abstract]   [Full Text] [Related]  

  • 4. Chemotherapy for anaplastic thyroid cancer using docetaxel and cisplatin: report of eight cases.
    Seto A; Sugitani I; Toda K; Kawabata K; Takahashi S; Saotome T
    Surg Today; 2015 Feb; 45(2):221-6. PubMed ID: 25734195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete response to weekly carboplatin-docetaxel chemotherapy in a 91-year-old woman with anaplastic thyroid cancer.
    Koussis H; Giorgi CA; Di Liso E; Carlucci MC; Fassina A; Marioni G; Conte PF
    Am J Otolaryngol; 2015; 36(2):268-72. PubMed ID: 25681954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA PTCSC3 affects drug resistance of anaplastic thyroid cancer through STAT3/INO80 pathway.
    Wang XM; Liu Y; Fan YX; Liu Z; Yuan QL; Jia M; Geng ZS; Gu L; Lu XB
    Cancer Biol Ther; 2018 Jul; 19(7):590-597. PubMed ID: 29561707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anaplastic Thyroid Carcinoma, Version 2.2015.
    Haddad RI; Lydiatt WM; Ball DW; Busaidy NL; Byrd D; Callender G; Dickson P; Duh QY; Ehya H; Haymart M; Hoh C; Hunt JP; Iagaru A; Kandeel F; Kopp P; Lamonica DM; McCaffrey JC; Moley JF; Parks L; Raeburn CD; Ridge JA; Ringel MD; Scheri RP; Shah JP; Smallridge RC; Sturgeon C; Wang TN; Wirth LJ; Hoffmann KG; Hughes M
    J Natl Compr Canc Netw; 2015 Sep; 13(9):1140-50. PubMed ID: 26358798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
    Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
    Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer.
    Wang Y; Hu Z; Ma W; Niu Y; Su J; Zhang L; Zhao P
    Invest New Drugs; 2021 Jun; 39(3):764-774. PubMed ID: 33245464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KLF5 influences cell biological function and chemotherapy sensitivity through the JNK signaling pathway in anaplastic thyroid carcinoma.
    Wang Z; Qiu X; Zhang H; Li W
    J Biochem Mol Toxicol; 2020 May; 34(5):e22469. PubMed ID: 32173973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-381-3p attenuates doxorubicin resistance in human anaplastic thyroid carcinoma via targeting homeobox A9.
    Zhang Y; Li K; Wang W; Han J
    Int J Exp Pathol; 2021 Aug; 102(4-5):209-217. PubMed ID: 34719830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxorubicin has a synergistic cytotoxicity with cucurbitacin B in anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Tumour Biol; 2017 Feb; 39(2):1010428317692252. PubMed ID: 28218042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA GAS5 inhibits cell proliferation and resistance to doxorubicin in anaplastic thyroid carcinoma by regulating miR-96.
    Song CQ; Wang M; Zhang SM; Ma XY
    J Biol Regul Homeost Agents; 2020; 34(5):1787-1792. PubMed ID: 33164472
    [No Abstract]   [Full Text] [Related]  

  • 14. A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer.
    Chintakuntlawar AV; Yin J; Foote RL; Kasperbauer JL; Rivera M; Asmus E; Garces NI; Janus JR; Liu M; Ma DJ; Moore EJ; Morris JC; Neben-Wittich M; Price DL; Price KA; Ryder M; Van Abel KM; Hilger C; Samb E; Bible KC
    Thyroid; 2019 Nov; 29(11):1615-1622. PubMed ID: 31595822
    [No Abstract]   [Full Text] [Related]  

  • 15. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
    Lopez JP; Wang-Rodriguez J; Chang C; Chen JS; Pardo FS; Aguilera J; Ongkeko WM
    Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1022-7. PubMed ID: 17938326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature.
    Arıkan R; Telli TA; Demircan NC; Başoğlu T; Ercelep Ö; Atasoy BM; Özgüven S; Dane F; Yumuk PF
    Curr Probl Cancer; 2021 Apr; 45(2):100668. PubMed ID: 33127167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.
    Iyer PC; Dadu R; Gule-Monroe M; Busaidy NL; Ferrarotto R; Habra MA; Zafereo M; Williams MD; Gunn GB; Grosu H; Skinner HD; Sturgis EM; Gross N; Cabanillas ME
    J Immunother Cancer; 2018 Jul; 6(1):68. PubMed ID: 29996921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Juglone-ascorbic acid synergy inhibits metastasis and induces apoptotic cell death in poorly differentiated thyroid carcinoma by perturbing SOD and catalase activities.
    Gaikwad S; Chakraborty A; Salwe S; Patel V; Kulkarni S; Banerjee S
    J Biochem Mol Toxicol; 2018 Sep; 32(9):e22176. PubMed ID: 29992683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining doxorubicin-nanobubbles and shockwaves for anaplastic thyroid cancer treatment: preclinical study in a xenograft mouse model.
    Marano F; Frairia R; Rinella L; Argenziano M; Bussolati B; Grange C; Mastrocola R; Castellano I; Berta L; Cavalli R; Catalano MG
    Endocr Relat Cancer; 2017 Jun; 24(6):275-286. PubMed ID: 28487350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxorubicin-Loaded Nanobubbles Combined with Extracorporeal Shock Waves: Basis for a New Drug Delivery Tool in Anaplastic Thyroid Cancer.
    Marano F; Argenziano M; Frairia R; Adamini A; Bosco O; Rinella L; Fortunati N; Cavalli R; Catalano MG
    Thyroid; 2016 May; 26(5):705-16. PubMed ID: 26906083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.